A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
about
A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.IL-17 Signaling: The Yin and the Yang.Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Review of IL-17 inhibitors for psoriasis.Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?Group 3 Innate Lymphoid Cells: Communications Hubs of the Intestinal Immune System.Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.Gut microbiome: a new player in gastrointestinal disease.Safety of biologics in psoriasis.Genetics of immune-mediated inflammatory diseases.The day will come to treat HCC in a drugstore?Divergent Roles of Interferon-γ and Innate Lymphoid Cells in Innate and Adaptive Immune Cell-Mediated Intestinal Inflammation.Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation.Shifting the Focus: The Primary Role of IL-23 in Psoriasis and other Inflammatory Disorders.An Open Letter to Health Canada.Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition.Human γδ T-Cell Control of Mucosal Immunity and Inflammation.Effector T Helper Cell Subsets in Inflammatory Bowel Diseases.Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab InfusionOf mice, men and immunity: a case for evolutionary systems biology
P2860
Q38373177-F32354FB-062C-4B10-9946-172D41818E00Q38645111-366C1748-93DB-4E41-A5C2-8147F0303FD2Q38761961-0705BCC5-4899-4718-8F52-BD83C81C2508Q39158530-9D2FAF8F-3822-4BB2-9B0A-99C220FDF545Q39315997-3453DF0B-1C31-4025-AF4F-83DE1C7059A0Q39458219-E0087C2A-8C30-48DF-9DB3-F696DCADB9D8Q44581309-B5A2E419-383B-41EC-8993-2E696F2A3C8BQ46131367-EF144E25-6CAC-46E8-8962-87AAD77C90BFQ46247849-EB75C36F-25ED-4869-BED6-CC4A7500BA53Q47138366-F89E151E-78EB-4823-8B10-FF107AEC8022Q47253021-81BEFFE0-4656-4CEA-9DA4-1D6D10D3199EQ47644680-D1F8278B-68B3-4DA1-BC97-97B837F7530BQ47727612-64DE7202-540D-44CC-AECF-4EFE52597E6CQ48113441-18FD5921-1E7E-4CDB-B967-223605000F52Q48144965-7A343FB5-2707-424C-A82A-22298C1481F5Q48254133-55338E33-A33D-4201-A34C-538954B9EDD0Q49174925-0FEB82A3-9261-4BAD-8508-2E8DEB534BB2Q49205651-E5EE3F75-795E-4113-B307-789128BAAD8AQ49551961-F8632F07-1697-46B2-86CB-E895DE190553Q50041283-2FA2A868-DB4D-4156-9A5A-D787F500282CQ50115604-39FBF7B8-998F-4408-92BB-88C8A70E62DDQ53828883-43407FFF-4464-4BD2-9335-89A11975B03DQ55006062-E0E09B30-F79C-4D69-8074-DE3C5A6F2227Q55176161-EF8273F3-C142-4AC6-A70C-F9775537E47DQ56334543-EA6ED68C-3A0F-41E2-9F81-0F7D6DC1BEC2Q58198899-0ACE0ED7-6BCE-4020-A4FA-6D46F13AB7B9
P2860
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A Randomized, Double-Blind, Pl ...... ate-to-Severe Crohn's Disease.
@en
A Randomized, Double-Blind, Pl ...... ate-to-Severe Crohn's Disease.
@nl
type
label
A Randomized, Double-Blind, Pl ...... ate-to-Severe Crohn's Disease.
@en
A Randomized, Double-Blind, Pl ...... ate-to-Severe Crohn's Disease.
@nl
prefLabel
A Randomized, Double-Blind, Pl ...... ate-to-Severe Crohn's Disease.
@en
A Randomized, Double-Blind, Pl ...... ate-to-Severe Crohn's Disease.
@nl
P2093
P2860
P356
P1476
A Randomized, Double-Blind, Pl ...... ate-to-Severe Crohn's Disease.
@en
P2093
Brian Feagan
Carol Landers
Gil Y Melmed
Paul Klekotka
Remo Panaccione
Richard Newmark
Shao-Lee Lin
Stephan R Targan
P2860
P2888
P304
P356
10.1038/AJG.2016.298
P407
P577
2016-08-02T00:00:00Z
P6179
1007306834